INFORME INAHTA - INFORME INAHTA
Publicador de contenidos
Objetivo: The objectives were to assess the clinical effectiveness and cost-effectiveness of the BioMonitor 2-AF™ (Biotronik SE & Co. KG, Berlin, Germany), the Confirm Rx™ (Abbott Laboratories, Lake Bluff, IL,USA), and the Reveal LINQ™ (Medtronic plc, Minneapolis, MN, USA) implantable cardiac monitors to detect suspected paroxysmal atrial fibrillation in people who have had a cryptogenic stroke. The review considered the diagnostic accuracy, clinical effectiveness and cost-effectiveness of the three implantable cardiac monitors compared with no further testing after at least 24 hours of outpatient external ambulatory electrocardiography.
Autoría: NIHR Health Technology Assessment programme
Año de publicación: 2020